Emerging Evidence on Coronary Heart Disease Screening in Kidney and Liver Transplantation Candidates
Published: October 17, 2022
- Coronary heart disease is a cause of mortality and morbidity for kidney and liver transplant candidates and recipients. This is due to traditional and nontraditional risk factors and a somewhat unique pathophysiology present in patients without end-stage organ disease.
- Optimizing strategies to disseminate and implement best practices for goal directed medical therapy in end-stage organ disease population should be prioritized to improve cardiovascular outcomes for transplant patients.
- This scientific statement discusses evidence from the last decade related to coronary heart disease screening, and management for kidney and liver transplant candidates and emphasizes multi-disciplinary engagement, including a dedicated cardiologist.
Supporting Materials
Recommended Reading
- 2016 Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients with Coronary Artery Disease
- 2018 Guideline on the Management of Blood Cholesterol
- 2014 Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery: Executive Summary
- 2020 Guideline for the Management of Patients With Valvular Heart Disease
- Cardiac Disease Evaluation and Management Among Kidney and Liver Transplantation Candidates